GGrantIndex
Sort

39,280 grants matching leukemia

POSITIONAL CLONING OF THE MEN1 GENE

$544,018
Settara Chandrasekharappa · National Human Genome Research Institute · ZIA · FY2009 · HG

Project 1: Clonal Dynamics Guiding Curative Therapies for Acute Myeloid Leukemia

$543,982
David T Scadden · Dana-Farber Cancer Inst · U54 · FY2016 · CA

Genetic Loss-of-Function Studies of SETD2 in Kidney Tumorigenesis

$543,901
Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA

Regulation and tumorigenesis of non-classical RAS oncoproteins - Resubmission

$543,820
Pau Castel · New York University School Of Medicine · R01 · FY2025 · CA

Regulation and tumorigenesis of non-classical RAS oncoproteins - Resubmission

$543,820
Pau Castel · New York University School Of Medicine · R01 · FY2024 · CA

Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD

$543,763
Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · R01 · FY2019 · HL

Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD

$543,763
Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · R01 · FY2020 · HL

Mechanistic Evaluations of ILC2 Cells for the Treatment/Prevention of GVHD

$543,763
Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · R01 · FY2017 · HL

Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells

$543,694
Johannes Zakrzewski · Hackensack University Medical Center · R37 · FY2023 · CA

The role of inflammation in the regulation of immune response in acute myeloid leukemia

$543,631
Iannis Aifantis · New York University School Of Medicine · R01 · FY2024 · CA

Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation

$543,567
Swapna Panuganti · Cellerant Therapeutics, Inc. · R42 · FY2019 · AI

Role of Runx1 in Pathologic Ocular Angiogenesis

$543,541
Leo A Kim · Schepens Eye Research Institute · R01 · FY2018 · EY

Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival

$543,381
Teresa M Reyes · University Of Cincinnati · R01 · FY2020 · NR

Targeted therapy of ALL with gene-modified central memory T cells

$543,264
Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2011 · CA

lncRNA regulation of glioblastoma progression and therapeutic resistance

$543,237
Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · NS

NOVEL LENTIVIRAL PSEUDOTYPES

$543,137
James K. Willson · Weill Medical Coll Of Cornell Univ · P01 · FY2008 · HL

Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms

$542,931
Lisa A Carey · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA

Predicting Clinical Outcome After Traditional and Ibrutinib-based Therapy In Chronic Lymphocytic Leukemia

$542,925
Tait D Shanafelt · Mayo Clinic Rochester · R01 · FY2015 · CA

The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML

$542,890
Guido Marcucci · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA

The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML

$542,890
Guido Marcucci · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA

Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

$542,767
Omar Abdel-Wahab · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA

Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors

$542,666
Michael J Borowitz · Johns Hopkins University · R01 · FY2007 · CA

Role of targeting ATPases BRG1/BRM in therapy of AML

$542,663
Warren Campbell Fiskus · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Validation of Therapeutic Target Genes in Human Liver Cancer

$542,657
Snorri Thorgeirsson · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Targeting the Ig-light chains with CAR-T cells in lymphoid tumors

$542,644
Gianpietro Dotti · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA